[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV.
Boyko AN, et al. Among authors: zaslavsky lg.
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4):86-96. doi: 10.17116/jnevro202412404186.
Zh Nevrol Psikhiatr Im S S Korsakova. 2024.
PMID: 38676683
Clinical Trial.
Russian.